Bioheart has entered into a joint venture with Magnum Cell Therapies.
Magnum Cell Therapies' mission is to provide the latest regenerative medicine therapies to patients suffering from degenerative diseases.
Magnum's facilities include a state of the art clinic and laboratory located in Honduras.
Bioheart will provide the necessary training and expertise to transfer Bioheart therapies to Magnum.
Bioheart and Magnum will work closely with the Honduran Ministry of Health to make Bioheart protocols part of the standard of care for patients in Honduras and neighboring countries.
Bioheart will assume 10% ownership of Magnum Cell Therapies.
Magnum will offer these therapies to the more than 8 million people living in Honduras as well as being a premier site for medical tourism.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity